Adenocarcinoma of the Rete Testis: Clinicopathologic and Immunohistochemical Characterization of 6 Cases and Review of the Literature.
Al-Obaidy KI, Idrees MT, Grignon DJ, Ulbright TM.
Am J Surg Pathol. 2019 May;43(5):670-681. doi: 10.1097/PAS.0000000000001219.
Adenocarcinoma of the Rete Testis: A Case Report.
Mitchell CF, Pearce S.
Cureus. 2022 Feb 14;14(2):e22210. doi: 10.7759/cureus.22210. eCollection 2022 Feb.
Adenocarcinoma of the rete testis: clinicopathological study of 18 cases with emphasis on MET amplification and a review of the literature.
Chen Y, Chen Y, Sun Q, Hou X, Fu S, Jin H, Tao X, Yang Y, Wang J, Cao Y, An X, Zhang Y.
Histopathology. 2025 Apr;86(5):762-771. doi: 10.1111/his.15383. Epub 2024 Dec 4.
Adenocarcinoma of the rete testis.
Glazier DB, Vates TS, Cummings KB, Antoun S.
World J Urol. 1996;14(6):397-400. doi: 10.1007/BF00183123.
[Clinicopathological features of adenocarcinoma of the rete testis].
Tao X, Chen Q, Zheng LM, Chen N, Chen YP, Chen H.
Zhonghua Bing Li Xue Za Zhi. 2021 May 8;50(5):488-493. doi: 10.3760/cma.j.cn112151-20200806-00629.
Adenocarcinoma of the rete testis.
Sánchez-Chapado M, Angulo JC, Haas GP.
Urology. 1995 Oct;46(4):468-75. doi: 10.1016/S0090-4295(99)80257-X.
Editorial Comment to A case of adenocarcinoma of the rete testis with durable response to cisplatin-based chemotherapy.
Yuasa T.
IJU Case Rep. 2021 Jun 21;4(5):271-272. doi: 10.1002/iju5.12326. eCollection 2021 Sep.
Adenocarcinoma of the Rete Testis: Seven Additional Cases, Including Exclusively and Predominantly Intrarete Tumors.
Al-Obaidy KI, Collins K, Idrees MT, Ulbright TM.
Am J Surg Pathol. 2021 Dec 1;45(12):1720-1724. doi: 10.1097/PAS.0000000000001771.
Primary adenocarcinoma of the rete testis with elevated serum CA19-9 antigen levels.
Kitano H, Sentani K, Goto K, Sekino Y, Yamanaka R, Nagasaka K, Shigematsu Y, Kobayashi K, Hayashi T, Yasui W, Teishima J.
Int Cancer Conf J. 2020 Aug 9;9(4):240-243. doi: 10.1007/s13691-020-00437-z. eCollection 2020 Oct.
A case of adenocarcinoma of the rete testis with durable response to cisplatin-based chemotherapy.
Owa S, Sasaki T, Uchida K, Watanabe S, Kato M, Sugino Y, Kato M, Masui S, Nishikawa K, Yoshio Y, Kanda H, Sugimura Y, Inoue T.
IJU Case Rep. 2021 Jun 19;4(5):267-271. doi: 10.1002/iju5.12298. eCollection 2021 Sep.
